Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06015802 | Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors | recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03637569 | The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer | recruiting | — | 1,000 | Samsung Medical CenterOTHER | 1 | Aug 25, 2023 |
| clinicaltrials |
| NCT05502198 | Relevance of Sarcopenia in Advanced Liver Disease(ACCESS-ESLD) | recruiting | — | 150 | Linkoeping UniversityOTHER_GOV | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06006650 | Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | recruiting | Phase 2 | 114 | Tang-Du HospitalOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT06001151 | Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative(ACHELOUS) | recruiting | Phase 2 | 49 | Qian ChuOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05994170 | Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma(CTVp1-NPC) | recruiting | N/A | 454 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05991856 | Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma | recruiting | — | 45 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05984342 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 | 50 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05980715 | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy(HNC-SYSU-003) | recruiting | Phase 3 | 324 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04722692 | Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ(SENTINOT_2) | recruiting | Phase 3 | 500 | Uppsala UniversityOTHER | 3 | Aug 3, 2023 | clinicaltrials |
| NCT05838053 | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | — | 446 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05830500 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | recruiting | Phase 4 | 360 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03786003 | ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007) | recruiting | N/A | 1,086 | Fudan UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05954897 | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05952661 | Minimally Residual of Esophageal Cancer 001(ECMRD-001) | recruiting | — | 56 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05837052 | A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC | recruiting | Phase 2 | 49 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05862168 | Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial | recruiting | Phase 2 | 30 | Weijia Fang, MDOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05945407 | Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer | recruiting | N/A | 57 | Peking University People's HospitalOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05943379 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | recruiting | Phase 2 | 85 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05941338 | Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC(HNC-SYSU-001) | recruiting | Phase 2 | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05940532 | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC | recruiting | Phase 2 | 41 | Hunan Cancer HospitalOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05935189 | Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens(TIR-HCC) | recruiting | — | 500 | Nikomed Medical CenterNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05934032 | National Network Genomic Medicine Lung Cancer, Germany(nNGM) | recruiting | — | 30,000 | Prof. Dr. Juergen WolfOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05926726 | GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | recruiting | N/A | 12 | RenJi HospitalOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05913089 | A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | recruiting | Phase 2 | 58 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05916755 | Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform(PORTRAIT) | recruiting | — | 100 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05917431 | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | recruiting | Phase 2 | 39 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT03919552 | Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 482 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04519151 | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | recruiting | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05649865 | Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)(MER-HPV) | recruiting | — | 150 | Region SkaneOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05608200 | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC | recruiting | Phase 3 | 427 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT04617756 | Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract(iNDUCT) | recruiting | Phase 2 | 50 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05877872 | Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 424 | Sun Yat-sen UniversityOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05872880 | TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. | recruiting | — | 124 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT04959604 | Lymph Node Mapping Via Flourescent Dye in Colon Cancer | recruiting | N/A | 30 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05870969 | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)(dSEARCH) | recruiting | — | 20,000 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05447702 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 35 | West China HospitalOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05862337 | Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. | recruiting | Phase 3 | 480 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT05860868 | Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05203120 | A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma | recruiting | N/A | 50 | University of AarhusOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05854823 | The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR | recruiting | N/A | 23 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | recruiting | Phase 3 | 244 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05778708 | Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer Patients | recruiting | N/A | 318 | The University of Hong KongOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04539977 | PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer | recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients(AxIn) | recruiting | Phase 2 | 118 | Consorzio OncotechOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT05688488 | Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords | recruiting | Phase 1 / Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05527470 | Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 440 | Wei JiangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2023source: clinicaltrials